Display options
Cite
Haffner ME, Whitley J, Moses M. Two decades of orphan product development. Nat Rev Drug Discov. 2002;1(10):821-5doi: 10.1038/nrd919.
Haffner, M. E., Whitley, J., & Moses, M. (2002). Two decades of orphan product development. Nature reviews. Drug discovery, 1(10), 821-5. https://doi.org/10.1038/nrd919
Haffner, Marlene E, et al. "Two decades of orphan product development." Nature reviews. Drug discovery vol. 1,10 (2002): 821-5. doi: https://doi.org/10.1038/nrd919
Haffner ME, Whitley J, Moses M. Two decades of orphan product development. Nat Rev Drug Discov. 2002 Oct;1(10):821-5. doi: 10.1038/nrd919. PMID: 12360259.
Copy Download .nbib Format: NLM
Share it on

Nat Rev Drug Discov. 2002 Oct;1(10):821-5. doi: 10.1038/nrd919.

Two decades of orphan product development.

Nature reviews. Drug discovery

Marlene E Haffner, Janet Whitley, Marie Moses

Affiliations

  1. Office of Orphan Products Development, US Food and Drug Administration, Room 15A08, 5600 Fishers Lane, Rockville, Maryland 20857, USA. [email protected]

PMID: 12360259 DOI: 10.1038/nrd919

Abstract

Over the past 20 years, incentives of the Orphan Drug Act (ODA), the largest single source of extramural clinical grants at the US Food and Drug Administration, have had a substantial impact on public health. ODA incentives have contributed to the development of many innovative biotechnology products, and as our understanding of the human genome evolves, it is anticipated that pharmacogenomics will result in the identification of more 'orphan diseases'.

MeSH terms

Publication Types